Introduction
Coordinated Ca 2þ handling in cardiac myocytes is essential for efficient excitation-contraction (E-C) coupling in the heart. Sympathetic stimulation of the heart through b-adrenergic receptors (b-ARs) increases the rate and force of cardiac muscle contraction and relaxation as part of the 'fight or flight' response. 1 In this pathway, activation of b-ARs leads to the production of cAMP, activation of protein kinase A (PKA), and phosphorylation of Ca 2þ regulatory proteins, including the L-type Ca 2þ channel (LTCC), phospholamban (PLN), ryanodine receptors (RYRs), troponin I, and myosin binding protein C. 2, 3 identified in the adult cardiac myocytes. For example, mAKAP (AKAP6) binds to RYR to mediate PKA-dependent RYR phosphorylation. AKAP18a (AKAP7a) targets LTCC to regulate Ca 2þ influx in response to b-adrenergic stimulation. 7, 8 AKAP18d (AKAP7d) interacts with SERCA-PLN to regulate SR Ca 2þ reuptake. 9 Murine AKAP150 (also referred to as AKAP5) or human AKAP79 has been shown to interact with key signalling enzymes such as PKA, PKC, and calcineurin and their potential substrates, including LTCC, b-ARs, caveolin 3, adenylyl cyclase. [10] [11] [12] [13] [14] [15] [16] [17] Importantly, deletion of AKAP150 resulted in the loss of badrenergic stimulated Ca 2þ transient and phosphorylation of RYR and PLN. 15 Moreover, loss of AKAP150 also disrupted intracellular trafficking of b-ARs in cardiac myocytes. 18 These results suggest that AKAP150 plays a critical role in regulating Ca 2þ cycling and E-C coupling in the heart. However, the functional relevance of the AKAP150 signalling complex in response to pathological stress remains unknown. In addition to targeting PKA, AKAP150 also binds to calcineurin, a protein phosphatase that has been implicated as a central regulator of cardiac hypertrophy. 19, 20 Calcineurin is activated in response to increased intracellular Ca 2þ , which in turn dephospholylates the transcription factor NFAT (nuclear factor of activated T cells), permitting its translocation from cytoplasm to nucleus to induce hypertrophic gene expression. 19, 20 In neurons, AKAP150 mediates targeted activation of the calcineurin-NFAT signalling, which serves as an important mechanism coupling LTCC Ca 2þ influx to gene expression. [21] [22] [23] Intriguingly, disruption of the binding of calcineurin to AKAP150 prevented LTCCmediated NFAT nuclear translocation, suggesting a highly localized calcineurin-NFAT activation through AKAP150/LTCC docking. 21 Similarly, it has been shown that a subgroup of LTCC in the localized caveolin-3 containing signalling domains provides a source of Ca 2þ to activate calcineurin-NFAT signalling in cardiomyocytes. 24 AKAP150, which binds to both LTCC and calcineurin, is also part of the caveolin-3 containing microdomains. 15 However, the potential role of AKAP150 in mediating calcineurin-NFAT signalling and hypertrophic response in cardiomyocytes has not been investigated. In this study, we found that AKAP150 expression was significantly decreased in the failing mouse heart after pressure overload. We generated a conditional cardiomyocyte-specific AKAP150 knockout mouse model to examine the role of AKAP150 in regulating cardiac Ca 2þ cycling, contractility, and myocardial remodelling following pathological stress. Importantly, ablation of AKAP150 in the heart promoted adverse pathological remodelling and functional deterioration following pressure overload or myocardial infarction (MI), suggesting an important cardio-protective role of AKAP150 in myocardial stress response. Mechanistically, AKAP150 is essential in regulating Ca 2þ cycling and cardiac ionotropy through targeted regulation of SR Ca 2þ handling proteins in response to stress. However, AKAP150-deficient mice displayed normal calcineurin-NFAT activation and hypertrophic response, suggesting that AKAP150 is dispensable in cardiac hypertrophic signalling.
Methods
Detailed methods are available in Supplementary material online.
Animal models
The generation of the AKAP150-/-mouse and AKAP150 loxP-targeted (fl) mouse was described previously. 25, 26 AKAP150 fl/fl mice were crossed with aMHC-Cre mice 27 to generate cardiac-specific AKAP150-deficient mice. The NFAT-luciferase reporter transgenic mouse, also described previously, 28 was crossed with the AKAP150-/-mouse. All experimental procedures with animals were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of University of Washington and National Institute of Health.
Echocardiography, transverse aortic constriction, MI, ischemia/reperfusion, and isoproterenol infusion
Mice were anesthetized with 2% isoflurane by inhalation.
Echocardiographic imaging was performed with a VisualSonics Vevo 2100 imaging system as described previously. 29 Transverse aortic constriction (TAC), MI, ischemia/reperfusion (IR), and isoproterenol infusion were performed as previously described. 30, 31 Mice were euthanized by CO 2 asphyxiation.
2.3 Histological analysis, cell size measurement, terminal deoxynucleotidyl transferase dUTP nick end labelling, and luciferase reporter assays
Histological analysis of fibrosis and cell surface area measurements were described previously. 29 Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) from paraffin sections was performed with a TMR Red In Situ Death Detection Kit (Roche Diagnostics) according to the manufacturer's instructions as described previously. 29 Luciferase reporter assays in mouse hearts or cultured cadiomyocytes were performed as described. ] i measurements, and cell shortening Ventricular myocytes were isolated using a Langendorff perfusion apparatus from adult mice euthanized with pentobarbital (100 mg/kg given IP) as previously described. 32 Primary neonatal rat cardiomyocytes were prepared from hearts of 1-to 2-day-old Sprague-Dawley rat pups anesthetized by isloflurane inhalation followed by decapitation. 30 32 These experiments were also performed in Tyrode's solution containing 100 nM isoproterenol.
Immunoprecipitation and Western blotting
Protein extraction from mouse heart or cultured cardiomyocytes and subsequent immunocprecipitation and Western blotting were performed as previously described.
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Statistics
Sample size was estimated by conducting pilot experiments and power analysis. Results are presented as means 6 SEM. Mann-Whitney U-test or Kruskal-Wallis test with post-hoc Mann-Whitney U-test and Bonferroni's correction was used for studies with small sample sizes. Two-way nested ANOVA with Tukey's post-hoc test was used for calcium and contractility data. P < 0.05 was considered statistically significant.
Results
Generation of cardiac-specific AKAP150 knockout mice
To study the function of AKAP150 in the heart in response to pathological stress, we first measured cardiac AKAP150 expression in mice subjected to pressure overload by TAC (27-gauge) for 4 weeks, which was used to induce pathological cardiac remodelling and heart failure (Supplementary material online, Figure S1 ). Importantly, AKAP150 expression was markedly decreased in the failing heart induced by TAC ( Figure 1A , Supplementary material online, Figure S1B ), suggesting a potential role for AKAP150 in regulating myocardial response to pathological stress. This prompted us to generate a cardiomyocyte-specific AKAP150 null mouse model using a Cre/LoxP-dependent conditional gene targeting approach. Mice homozygous for the AKAP150-LoxP targeted allele (AKAP150fl/fl) 26 were crossed with cardiomyocyte-specific aMHC-Cre transgenic mice 27 , which drives Cre recombinase expression in neonatal heart proceeding to adulthood. Western blot analysis showed efficient deletion of AKAP150 in the heart as well as in isolated cardiomyocytes from the AKAP150fl/fl-aMHC-Cre mice ( Figure 1B , Supplementary material online, Figure S1D ). The AKAP150fl/fl-aMHCCre mice were generated at the predicted Mendelian ratios and were overly normal well into the adulthood, with no changes in cardiac performance as assessed by echocardiography and no signs of cardiac hypertrophy as measured by heart weight/body weight ratio (HW/BW) at 2 months of age ( Figure 1C-E) . Similarly, mice with global deletion of AKAP150 showed no detectable basal phenotype ( Figure 1F-I) . The expression of other AKAP isoforms in the heart was not altered in AKAP150-deficient mice ( Figure 1F ).
3.2 AKAP150 deficient mice are predisposed to adverse cardiac remodelling and dysfunction following pressure overload Next, we investigated the role of AKAP150 in regulating pathological stress response and heart failure propensity. The AKAP150fl/fl-aMHCCre mice and littermate controls were subjected to chronic pressure overload by TAC (27-gauge) for 0-4 weeks to analyse their susceptibility to heart failure. The AKAP150-deficient mice developed more prominent ventricular dilation and cardiac dysfunction compared with AKAP150fl/fl control mice 4 weeks after TAC, as indicated by significantly increased left ventricular dimension (LVED), decreased fractional shortening (FS), and increased ventricular wall thickness (Figure 2A-D) . Cardiomyocytes from AKAP150-deficient mice also showed more prominent elongation after TAC (Supplementary material online, Figure  S2 ). This was associated with enhanced pathological hypertrophy as assessed by heart weights normalized to body weights (HW/BW), as well as increased pulmonary oedema as measured by lung weights normalized to body weights (LW/BW; Figure 2E and F), indicating more severe heart failure and exacerbated pathological remodelling in the AKAP150-deficient mice. Moreover, hearts from the AKAP150-deficient mice showed increased apoptosis and fibrosis after TAC compared with control mice, as assessed by TUNEL and Masson's trichrome staining of cardiac sections ( Figure 2G-I) . No significant difference in cardiac function or histology was detected in aMHC-Cre only mice (data no shown). Thus, ablation of AKAP150 predisposed the heart to dilated cardiomyopathy with severe cardiac dysfunction and pathological remodelling, suggesting a critical role for AKAP150 in regulating myocardial homeostasis and heart failure susceptibility following pathological stress.
3.3 Loss of AKAP150 promotes pathological remodelling and heart failure progression after MI We investigated the role of AKAP150 signalling in another experimental model of heart failure induced by MI. Here we subjected the AKAP150fl/ fl-aMHC-Cre mice and littermate controls to 2 weeks of MI to assess pathological remodelling and heart failure propensity. Echocardiographic analysis showed more pronounced ventricular dilation with wall thinning in the AKAP150-deficient mice compared with controls after 2 weeks of MI ( Figure 3A and B) . The AKAP150fl/fl-aMHC-Cre mice also showed worse ventricular performance than control mice after MI ( Figure 3C) . Intriguingly, AKAP150fl/fl-aMHC-Cre mice developed exaggerated cardiac hypertrophy (increased HW/BW) as well as pulmonary edema (increased LW/BW), an indicator of heart failure ( Figure 3D and E). Masson's trichrome staining of cardiac sections showed more expansive and thinner scars with increased chamber dilation in the AKAP150fl/flaMHC-Cre mice compared with controls ( Figure 3F and G). Interestingly, an increase in TUNEL positive cardiomycytes, corresponding to increased apoptotic cell death, was also detected in the AKAP150-deficient hearts ( Figure 3H and I). However, there was no significant difference in infarct area normalized to area at risk (IA/AAR) between AKAP150-deficient mice and controls after 1 h ischemia plus 24 h reperfusion (I/R, Supplementary material online, Figure S3 ), suggesting that AKAP150 doesn't regulate acute myocardial injury. These data indicate that ablation of AKAP150 in the heart promoted pathological remodelling, functional decomposition, and heart failure progression following MI, further suggesting a cardioprotective role of AKAP150 upon pathological stress.
3.4 AKAP150 is a critical regulator of cardiac calcium handling proteins in response to adrenergic stimulation or pressure overload AKAP150 has been shown to play an important role in regulating Ca 2þ cycling and E-C coupling in cardiomyocytes by interacting with multiple signalling proteins. [11] [12] [13] [14] [15] Here we examined the role of AKAP150 in regulating Ca 2þ regulatory proteins in cardiomyocytes under basal conditions as well as after pathological stimulation. First, we performed a co-immunoprecipitation experiment to determine potential interactions between AKAP150 and Ca 2þ regulatory proteins in the heart. AKAP150 was immunoprecipitated in cardiac extracts from wildtype or AKAP150-/-mice, followed by Western blot analysis with the indicated antibodies ( Figure 4A ). We observed that three key SR Ca 2þ regulatory proteins, RYR2, SERCA2, and PLN, interacted with AKAP150 to form a signalling complex in wild-type hearts ( Figure 4A ).
Immunoblot detection of one of the known AKAP150 binding partners PKA served as an internal control ( Figure 4A ). These proteins were not detected from the immunoprecipitates obtained from AKAP150-/-hearts. As a negative control, no specific proteins were immunoprecipitated with normal pre-immune IgG ( Figure 4A ). Importantly, pressure overload further increased the interaction of AKAP150 with PKA, as well as with RYR2 (Supplementary material online, Figure S4 ). No significant changes in the association between AKAP150 and SERCA2 or PLN were observed. Next, we examined phosphorylation status of SR Ca 2þ regulatory proteins in cardiomyocytes isolated from wild-type and 15 increased phosphorylation of PLN and RYR2 was induced by isoproterenol in wild-type cells, and this effect was largely blocked in AKAP150-/-cells, suggesting AKAP150 is a critical regulator of SR Ca 2þ regulatory proteins ( Figure 4B and C). We then determined the role of AKAP150 in regulating SR Ca 2þ regulatory proteins in response to pathological stimulation. We assessed phosphorylation of PLN and RYR2 from cardiac extracts of AKAP150fl/fl-aMHC-Cre and AKAP150fl/fl mice subjected to TAC (27-gauge) for 1 week. TAC stimulation induced an increase in PLN and RYR2 phosphorylation in AKAP150fl/fl mice, and this effect was again blunted in AKAP150fl/fl-aMHC-Cre mice ( Figure 4D and E). These data therefore suggest a critical role for AKAP150 in regulating Ca 2þ handling proteins in the heart upon pathological stimulation.
AKAP150-/-
3. ] i transients was measured from Wt and AKAP150-/-cells ( Figure 5A and B) . Stimulation with isoproterenol induced a significant increase in Ca 2þ amplitude in Wt cells, which was significantly inhibited in the AKAP150-/-cells ( Figure 5A and B) . Based on the observation that AKAP150 regulates phosphorylation of PLN and RYR2, we hypothesized that AKAP150 may directly influence SR Ca 2þ load. Similar levels of SR Ca 2þ load were detected in AKAP150-/-and Wt cells at basal conditions ( Figure 5C -E). Adrenergic stimulation with isoproterenol induced a significant increase in SR Ca 2þ load in Wt cells, but only a slight increase was detected in AKAP150-/-cells ( Figure  5C -E). Consistent with these observations, adrenergic stimulation of myocyte contractility was also largely inhibited in AKAP150-/-cells, indicating reduced contractility reserve ( Figure 5F ). Lastly, we determined the effect of AKAP150 deletion on Ca 2 þ cycling and myocyte contractility in mice subjected to pressure overload by TAC. Compared with control cells, AKAP150-deficient cardiomyocytes showed impaired Ca 2þ cycling and myocyte contractility at early stage of pressure overload by 1-week TAC ( Figure 5G and H). These data indicate that AKAP150 is an important regulator of Ca 2þ cycling and myocyte contractility following pathological stimulation, thus revealing a critical role for AKAP150 in maintaining Ca 2þ homeostasis and myocyte ionotropy.
AKAP150 is dispensable for the activation of calcineurin-NFAT signalling in cardiomyocytes and cardiac hypertrophy response
In addition to targeting PKA, AKAP150 has also been implicated in regulating calcineurin signalling, 23 ,34 a key regulator of cardiac hypertrophy. 19, 20 Whether AKAP150 is required for the activation of calcineurin-NFAT signalling in cardiomyocytes and/or the cardiac hypertrophic response has not been investigated. First, we examined if AKAP150 regulates calcineurin-NFAT signalling in cardiomyocytes. Rat neonatal cardiomyocytes were infected with an adenovirus encoding NFATc1-GFP along with lentiviral vectors expressing shRNA for AKAP150 (shAKAP) or a scrambled sequence (shScram), followed by stimulation of hypertrophic agonists. Robust nuclear translocation of NFATc1 was induced in shScram control cells by overexpression of the constitutively active truncated calcineurin (DCnA) or stimulation with ionomyocin or phenylephrine ( Figure 6A and B) . shRNA-mediated gene silencing of AKAP150 had no significant effect on agonist-induced NFATc1 nuclear translocation ( Figure 6A-C) . This observation was confirmed using wild-type and AKAP150-/-MEFs (Supplementary material online, Figure S4 ). Next, cardiomyocytes were infected with adenoviral vectors expressing an NFAT-dependent luciferase reporter cassette to examine if AKAP150 regulates endogenous NFAT transcriptional activity. Luciferase activity was induced by hypertrophic agonists phenylephrine, ionomyocin, and active calcineurin, which was not affected by AKAP150 deletion ( Figure  6D) . To determine the effect of AKAP150 deletion on NFAT transcriptional activity in the heart in vivo, we crossed AKAP150-/-mice with the NFAT-luciferase reporter mice 28 . AKAP150-/-mice displayed similar NFAT activity as AKAPþ/þ mice at baseline ( Figure 6E) . Surprisingly, deletion of AKAP150 mildly increased pressure overload-induced NFAT activity after TAC stimulation ( Figure 6E ). In addition, cardiomyocyte hypertrophic growth induced by phenylephrine was not altered by AKAP150 ablation ( Figure 6F) . Therefore, AKAP150 is not essential for calcineurin-NFAT activation in neonatal cardiomyocytes, nor is required for the cardiomyocyte hypertrophic response.
To assess the role of AKAP150 in regulating cardiac hypertrophy in vivo, AKAP150fl/fl mice with or without aMHC-Cre were subjected to pressure overload by TAC stimulation (27-gauge) for 1 week. This short pressure overload protocol was used here because prolonged TAC stimulation predisposes the AKAP150-deficient mice to heart failure ( Figure 2) , which may secondarily affect the development of heart hypertrophy. Surprisingly, similar hypertrophic response was detected in the AKAP150-deficient mice and littermate controls, as assessed by HW/ BW ratios and myocyte surface area measurements ( Figure 6G and H) . Chronic infusion of isoproterenol was used as another hypertrophic stimulus to extend and validate the results of pressure overload. Once again, the AKAP150fl/fl-aMHC-Cre mice showed no reduction in cardiac hypertrophic growth at the whole organ or cellular level compared with control mice after isoproterenol infusion ( Figure 6I and J) . Similar hypertrophic response was also observed in the AKAP150-/-mice compared with wild-type controls (Supplementary material online, Figure S5 ). These data clearly indicated that AKAP150 is not directly involved in cardiac hypertrophic response in vivo.
Discussion
This study reveals a critical role for AKAP150 in regulating myocardial remodelling and heart failure susceptibility in response to pathological stress. We show that loss of AKAP150 predisposed the heart to adverse remodelling, ventricular dysfunction, and heart failure following pressure overload or MI, revealing a cardioprotective role for AKAP150 upon pathological stimulation. However, AKAP150 seems dispensable for calcineurin-NFAT activation and cardiac hypertrophic response. Importantly, we identified three SR Ca Progressive cardiac hypertrophy and chamber dilation have been reported in global AKAP150 knockout mice. 35 However, we observed no overt basal cardiac phenotype in our AKAP150-/-mice within 3 months of age, which were maintained on the C57BL/6 genetic background (Figure 1) . In this study, we generated cardiac-specific AKAP150 knockout mice to examine cardiomyocyte autonomous role of AKAP150 in the heart, thereby circumventing the potential confounding changes associated with global AKAP150 deletion. Indeed, AKAP150 expressed in vascular smooth muscle cells mediates PKC-dependent regulation of vascular tone, and AKAP150-/-mice are naturally hypotensive and do not develop angiotensin II-induced hypertension. 16 In addition, AKAP150 expressed in neurons regulates synaptic plasticity and behaviour, and also affects the activity of autonomic nervous system. 26, 36 Thus, our conditional targeting approach bypasses potential abnormalities observed with the conventional gene deletion and allows for functional assessment of AKAP150 in the heart under both physiological and pathological conditions. We observed that AKAP150 expression was markedly decreased in the failing mouse heart after chronic pressure overload. Similarly, decreased AKAP150 expression was also observed in the lung from patient with chronic obstructive pulmonary disease. 37 On the other hand, AKAP150 expression was increased in adipocytes from exercise trained rats. 38 At present, the signalling mechanisms that regulate AKAP150 expression and processing remain unclear. In addition to contractile dysfunction, we showed that AKAP150 deficient mice developed exacerbated ventricular dilation, interstitial fibrosis, and myocyte hypertrophy following pressure overload or MI. Although we observe no changes in IA/AAR after acute IR, indicating AKAP150 has no direct role in acute ischemic myocardial injury, we detected a significantly increase in scar size in AKAP150-deficient mice after 2-week MI compared with control mice. The increased scar size indicates more severe pathological remodelling (fibrosis, scar expansion, and ventricular dilatation) in AKAP150-deficient mice after chronic MI. Therefore, ablation of AKAP150 promotes pathological cardiac remodelling after chronic MI, but not acute myocardial injury. Downregulation of AKAP150 following sustained pathological stress may contribute to disease progression and heart failure susceptibility. It has been shown that diminished myocardial contractility was sufficient to promote pathological myocardial remodelling, presumably by invoking an increase in adrenergic drive and reactive signalling. 39 For example, decreased cardiac contractility by phospholamban overexpression 40 or a dominant negative mutation 41 can induce adverse myocardial remodelling and heart failure in an otherwise normal setting. On the other hand, enhanced cardiac contractility with phospholamban inhibition 42 , could also potentially lead to defects in Ca 2þ cycling. Genetic manipulations that improve Ca 2þ cycling by adenoviral mediated SERCA overexpression or genetic ablation of PLN have been proven to be beneficial in attenuating heart failure. 39 As a future direction, it will be important to determine if transgenic overexpression of AKAP150 in the heart could preserve Ca 2þ cycling and contractile function in the setting of heart failure.
Our study provides new insights into the functional role of AKAP150 signalling in the heart under pathological conditions. During pathological stress such as TAC and MI, the myocardium adapts by increasing calcium cycling and myocyte contractility via adrenergic stimulation. This involves PKA-mediated phosphorylation of calcium handling proteins. Our data indicate that AKAP150 is required in this process by targeting PKA to key calcium regulatory proteins. Indeed, loss of AKAP150 led to impairments in phosphorylation of calcium regulatory proteins, calcium transient, SR calcium load, and myocyte contractility in response to stress. Mechanistically, AKAP150 co-immunoprecipitates with RYR2, SERCA2, and PLN to form a multimolecular signalling complex that also contains PKA and calcineurin. Ablation of AKAP150 inhibited phosphorylation of RYR2 and PLN, leading to decreased SR Ca 2þ load and Ca 2þ amplitude.
This underlies the reduced contractility reserve and increased heart failure susceptibility in the AKAP-deficient heart following pathological stress. AKAP150 has also been shown to interact with LTCC (Cav1.2) at sarcolemma and T-tubules, 11, 15, 17 47 although the functional relevance in vivo has not been determined. We speculate that different AKAPs signalling complexes may display redundant roles to sequester slightly different combinations of enzymes to specific targets. The utility of this mechanism provides a versatile means to respond to the continually changing signalling environment within myocytes. Future studies will address this possibility and functional roles of other AKAPs in the heart during physiological and pathological conditions. Since AKAP150 also targets calcineurin, a central player in cardiac hypertrophy, we also investigated the potential role of AKAP150 in mediating calcineurin-NFAT signalling in cardiomyocytes and cardiac hypertrophy, although this was not a main focus of this study. Surprisingly, our data showed that AKAP150 is not necessary for calcineurin-NFAT signalling in cardiomyocytes in vitro, or pressure overload-or agonist-induced cardiac hypertrophic response in vivo. In contrast, AKAP150 has been shown as a calcineurin-anchoring protein in smooth muscle cells and neurons, where it plays an important role in coupling local Ca 2þ -dependent calcineurin activation to NFATmediated gene expression. 16, 17, 22 Therefore, the role of AKAP150 seems to be cell type specific, and although AKAP150 anchors calcineurin, this doesn't seem to be coupled to NFAT activation or hypertrophic response in cardiomyocytes. Intriguingly, the AKAP150-deficient mice developed greater cardiac hypertrophy that control mice following chronic pressure overload. This increased hypertrophic response was likely attributable to more severe pathological myocardial remodelling with cardiac dilation and fibrosis due to cardiac decompensation in the AKAP150-deficient mice. It is formally possible that other AKAP(s) might be involved in calcineurin-NFAT-mediated hypertrophic signalling or that AKAP150 manages the actions of other NFAT isoforms in the myocardium. Indeed, mAKAP has been reported as another calcineurinanchoring protein in cardiomyocytes, and mAKAP depletion inhibited adrenergic-mediated NFATc1 translocation and hypertrophic growth in cultured myocytes. 48 A recent study using cardiac-specific mAKAP knockout mice further demonstrated that mAKAP is important for cardiac hypertrophy induced by pressure overload, catecholamine, and exercise. 44 Another cardiac AKAP, AKAP-lbc, mediates a-adrenergic receptor-mediated cardiomyocyte hypertrophy in vitro, possibly through its interaction with the PKD-HDAC5 signalling pathway. 49, 50 In conclusion, our study revealed an important role for the scaffold protein AKAP150 in regulating Ca 2þ cycling and myocyte ionotropy following pathological stress, through targeted regulation of SR Ca 2þ handling proteins. AKAP150 expression in the heart was markedly decreased after sustained pathological stimulation, and ablation of AKAP150 led to impaired Ca 2þ cycling and reduced contractility reserve, which were associated with increased pathological remodelling and heart failure susceptibility. The finding that AKAP150 plays a cardioprotective role upon pathological stress suggests that AKAP150 could serve as a potential diagnostic or therapeutic target for heart failure. Further work will be necessary to determine how and to what extent the AKAP150 signalling complex can be targeted to regulate Ca 2þ cycling and myocyte contractility in the setting of heart failure.
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